0

Effect of Zinc Acetate Dihydrate (NobelzinR) Treatment on Anemia and Taste Disorders in Patients With Chronic Kidney Disease With Hypozincemia

Daisuke Sato, Tomohito Gohda, Masao Kihara, Yasuhiko Kanaguchi, Takashi Kobayashi, Satoshi Mano, Yu Sasaki, Nao Nohara, Maki Murakoshi, Junichiro Nakata, Hitoshi Suzuki, Seiji Ueda, Satoshi Horikoshi, Yusuke Suzuki

Acta Med Okayama. 2018 Oct;72(5):535-538.

PMID: 30369613

Abstract:

Some patients with chronic kidney disease (CKD) receiving hemodialysis develop erythropoietin-resistant anemia, possibly due to zinc deficiency. The frequency of zinc deficiency in CKD (stages 1-5 and 5D) and CKD improvement via zinc supplementation are not completely verified. Here 500 CKD patients (Stage 1/2, n=100; Stage 3, n=100; Stage 4, n=100, Stage n=5, 100; Stage 5D, n=100) will be recruited to determine the frequency of serum zinc deficiency at each CKD stage. Patients with serum zinc concentrations <80 μg/dL will be treated with zinc acetate dihydrate (NobelzinR) to evaluate its effects on hypozincemia, taste disturbances, and anemia.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP5970456 Zinc acetate dihydrate Zinc acetate dihydrate 5970-45-6 Price
qrcode